XBiotech Inc. — 2019 Form 10-K Summary
Business context and reporting period
XBiotech is a pre-commercial biopharmaceutical company developing naturally derived “True Human” monoclonal antibodies for inflammatory and infectious diseases. This filing covers the fiscal year ended December 31, 2019; it was filed March 16, 2020. The defining event was the December 2019 sale to Janssen of bermekimab and related intellectual property.
Financial performance and position
- Revenue: The company reported no revenue for 2019, 2018 or 2017. It has not generated commercial product sales. Janssen-related manufacturing and transition-service arrangements provide for payments, including quarterly manufacturing payments through 2021.
- Profit and expenses: 2019 net income was $668.6 million, versus a $21.1 million net loss in 2018. The 2019 result chiefly reflects a $750.0 million gain from the Janssen transaction, less $49.8 million of income tax expense and operating expenses. Operating expenses were $31.2 million, including $24.1 million in research and development and $7.1 million in general and administrative costs. Operating loss was $31.2 million.
- Cash flow: Operating activities used $18.3 million in 2019. Investing activities provided $674.8 million, primarily reflecting $675.0 million received from Janssen. Financing activities provided $42.1 million, including proceeds from a share issuance and option exercises.
- Liquidity: At year-end, cash and cash equivalents were $714.6 million; the company also reported a $75.0 million escrow receivable, working capital of $656.1 million and total assets of $816.9 million. The filing says Janssen-related resources were expected to fund research and development for the next two years, and that cash was expected to last at least one year from the report date.
- Debt and capital: The company described its owned Austin campus and structures as debt-free. The balance sheet reports no borrowings. Total liabilities were $61.2 million and shareholders’ equity was $755.6 million.
- Margins: Product margins are not meaningful because the company had no product sales. The reported annual profit is not representative of recurring operating performance.
Material changes versus prior periods
- Net income shifted from losses in 2018 and 2017 to a large 2019 profit because of the one-time Janssen transaction; operating activities remained cash-consuming.
- Cash rose from $15.8 million at year-end 2018 to $714.6 million at year-end 2019, largely due to the Janssen payment. Research and development expense increased 53% year over year, primarily from clinical-trial activity, supplies and staffing.
- In February 2020, after year-end, XBiotech completed a $420 million modified Dutch auction tender offer, repurchasing 14 million shares at $30 each. The company reported 28,852,927 shares outstanding as of March 16, 2020 and said it was considering additional repurchases.
Outlook, commentary and risks
- The Janssen transaction provided $675 million at closing, with $75 million placed in an interest-bearing escrow account for 18 months, and eligibility for up to $600 million in additional milestones. Milestones depend on Janssen’s development and commercialization decisions, regulatory authorizations and specified timing; none was recognized as assured income.
- XBiotech retained rights to develop new anti-IL-1α antibodies for non-dermatology uses, subject to the transaction agreements. Management planned to advance multiple candidates, with re-entry into clinical development targeted beginning in early 2021. It also planned a 30,000-square-foot R&D center.
- Ongoing Phase II bermekimab studies in atopic dermatitis and hidradenitis suppurativa were being conducted for Janssen; the relevant INDs transferred to Janssen in January 2020. XBiotech also described infectious-disease programs, including varicella, C. difficile, influenza and S. aureus, at varying stages of development.
- Management expects significant and increasing operating losses as it develops its pipeline and states that profitability may not be achieved or sustained. The company has no approved products and depends on clinical success, regulatory approval, market adoption and future financing or collaboration income.
- Key risks include clinical-trial failure or delay, regulatory and manufacturing requirements, competition, intellectual-property challenges, dependence on key personnel, reliance on Janssen payments and the possibility that milestone payments are never earned. The filing also warns that COVID-19-related disruption could affect clinical-trial enrollment, suppliers and operations.
- The 2019 financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to attest to internal-control effectiveness.
Most important facts for investors to verify
- Janssen transaction terms, including the timing and conditions for release of the $75 million escrow and the contingent nature of up to $600 million in milestones.
- Cash, escrow and remaining liquidity after the February 2020 $420 million tender offer, including subsequent expenditures and any further repurchases.
- Progress, enrollment, results and timelines for XBiotech’s retained pipeline and Janssen-run Phase II studies.
- Expected research, development and facility spending relative to management’s stated cash-runway estimates.
- Whether manufacturing and transition-service obligations to Janssen are performed as contracted and generate the expected payments.